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BACKGROUND: The prognosis of squamous cell carcinoma of the oral tongue is poor and it would be beneficial to find prognostic
markers to better adjust treatment. Bmi-1 controls cell cycle and self-renewal of tissue stem cells, transcription factor c-myc affects
cell proliferation and apoptosis, and Snail regulates epithelial–mesenchymal transition. The expression of these markers has been
connected to prognosis in many cancer types.
METHODS: Bmi-1, c-myc, and Snail expressions were studied in our material consisting of 73 primarily T1N0M0 oral tongue carcinoma
patients. We compared the immunoexpressions of Bmi1, c-myc, and Snail with clinical parameters including the degree of histological
differentiation, tumour size, TNM classification, depth of invasion, and resection margins. In addition, survival analyses were
performed, comparing disease-free survival time with the registered protein expression of the markers mentioned above.
RESULTS: A significant correlation between Bmi-1 protein expression and recurrence (log-rank test, P¼0.005) was detected. Snail and
c-myc expression did not correlate with prognosis. Snail expression correlated with histopathological grade (Fisher’s exact test,
P¼0.007) and with the invasion depth of tumours (w
2-test, P¼0.037).
CONCLUSION: Negative Bmi-1 immunoexpression might serve as a marker of poor prognosis in oral tongue carcinoma patients.
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Squamous cell carcinoma (SCC) is the most common malignancy
of the upper aerodigestive tract (Barnes et al, 2005). Dissemination
of SCC through lymphatic routes may occur in the early course of
the disease. Presence of lymph node metastasis is considered the
most important tumour-related adverse prognostic factor in head
and neck SCC (Ferlito et al, 2002a,b; Howell and Grandis, 2005). In
individual patients, the TNM classification does not reliably
predict clinical outcome; even small T1 oral SCCs (OSCC) may
have occult nodal metastasis and may potentially behave
aggressively (Keski-Sa ¨ntti et al, 2007). Identifying these patients
is important for optimal treatment planning. In many studies, the
histological grade of OSCC is found to be non-predictive, although
some studies claim the opposite (Al-Rajhi et al, 2000; Keski-Sa ¨ntti
et al, 2007; Silveira et al, 2007; Arduino et al, 2008). It seems that
the most important histopathological predictor of nodal metastasis
and poor survival is the depth of tumour infiltration (Woolgar,
2006). It has been suggested, however, that the value of depth of
infiltration in clinical decision making is limited because of poor
specificity in identifying high-risk patients (Keski-Sa ¨ntti et al,
2007).
Bmi-1 is an essential constituent of the polycomb repressive
complex 1, a key epigenetic regulator. Through chromatin and
histone modifications (for example, methylation), it controls the
cell cycle and self-renewal of tissue stem cells (Spivakov and
Fisher, 2007). Bmi-1 can influence the central tumour suppressors
Rb and p53 by suppressing the p16
Ink4a/p19
Arf locus (Molofsky
et al, 2005). Bmi-1 is overexpressed in OSCC cells when compared
with normal mucosa and is thought to influence cell proliferation
and survival in oral carcinogenesis (Kang et al, 2007). Over-
expression of Bmi-1 is found to correlate with poor prognosis in
the non-keratinising type of nasopharyngeal carcinoma, breast,
and hepatocellular carcinoma, as well as in nervous system
tumours such as oligodendrogliomas and medulloblastomas, and
correlation with tumour stage has been reported in non-small-cell
lung cancer (Kim et al, 2004; Leung et al, 2004; Song et al, 2006;
Ha ¨yry et al, 2008; Vrzalikova et al, 2008; Wang et al, 2008).
The c-myc proto-oncogene was first detected in Burkitt’s
lymphoma, but has later been connected to many other cancers,
including breast and colon carcinomas, neuroblastomas,
osteosarcomas, and melanomas (Pelengaris et al, 2002). C-myc is
a transcription factor that activates many other genes and effects,
for example, cell proliferation and apoptosis. Both Bmi-1 and
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sc-myc are capable of immortalising certain cells in vitro and these
factors converge on the same pathways as c-myc signalling can
influence Bmi-1 activity and vice versa (Jacobs et al, 1999; Dimri
et al, 2002; Gil et al, 2005; Guney et al, 2006). C-myc is also
assumed to participate in oral carcinogenesis, and downregulation
of c-myc mRNA has even been associated with poor prognosis
(Vora et al, 2007; Koehn et al, 2008).
Snail is a zinc-finger transcription factor essential for epithelial–
mesenchymal transition because it downregulates the expression of
cell adhesion and basement membrane proteins, most importantly
cadherins (Batlle et al, 2000). Thus, cells gain a fibroblast-like
phenotype capable of migration and also enhanced invasiveness, as
has been shown in SCC cells (Takkunen et al, 2006, 2008). In
OSCC, the loss of cell adhesion molecules (for example, E-cadherin
and b-catenin), the downregulation of which is linked to Snail
expression, has been associated with tumour differentiation (Zidar
et al, 2008). In OSCC, Snail immunopositivity has been detected
predominantly only in the invasive front, and the overall
expression has been very low (Zidar et al, 2008). However, no
association with metastases has been observed (Mahomed et al,
2007), even though in another epithelial carcinoma, oesophageal
SCC, Snail expression in the invasive tumour front seems to
correlate with lymph node metastases, as well as with clinico-
pathological tumour stage (Usami et al, 2008).
With regard to the management of OSCC, it would be
remarkably advantageous to find prognostic markers that better
predict clinical outcome. For this study, we selected early-stage
oral tongue SCCs (T1N0M0 and T2N0M0) that were all treated with
curative intent in a fairly uniform manner (Keski-Sa ¨ntti et al,
2006). Immunoexpression of Snail, Bmi-1, c-myc, and Ki-67 in oral




Patient characteristics were the same as described by Keski-Sa ¨ntti
et al (2006, 2007). In summary, clinicopathological data of 141
patients diagnosed with SCC of the oral tongue at the Helsinki
University Central Hospital between 1992 and 2002 were reviewed.
Only patients with tumours clinically defined as T1/T2N0,
original histopathological material available for review, and
clinical follow-up data of a minimum of 24 months or until
death were included in the study. The dates and causes of death
were provided by Statistics Finland, the national agency of
population statistics. A total of 73 patients were eligible for
inclusion (36 men and 37 women, median age 59 years, range
23–95 years). Of the tumours, 35 (48%) had been clinically
classified as T1 and 38 (52%) as T2. All patients had undergone
resection of the primary tumour. In 31 patients, there had been no
further treatment primarily. A total of 42 patients underwent elective
neck treatment (neck dissection: n¼9; neck dissectionþ
radiotherapy: n¼32; radiotherapy: n¼1). All patients were
treated with curative intent.
The original histological sections of each patient were
re-assessed and tumour grade and depth of invasion were
determined by a single experienced head and neck pathologist (IL).
Tissue array blocks
For tissue microarray blocks, we selected three different areas in two
sets from normal haematoxyllin–eosin blocks from each patient to
be detached with a 1mm punch and placed into a paraffin block
with a tissue manual microarrayer (BeecherInstruments Inc, Silver
Spring, MD, USA). The first area was selected close to the surface
epithelium, the next in the middle of the tumour, and the last at the
invading front. Two parallel tissue array blocks were produced for
immunostainings. In eight patients, all array spots were missing or
included no tumour tissue. In these non-representative cases, we
accomplished the study by staining sections from whole tumour
blocks in five cases, but representative tissue was lacking for three
cases.
Immunohistochemistry
Tissue microarray-block slides and tissue slides were cut into
4mm-thick sections, deparaffinised in xylene, rehydrated through
graded alcohol series, and treated in a PT-module (LabVision UK
Ltd, Runcorn, UK) in Tris-HCl buffer (pH 8.5) for 20min at 981C
and with 0.3% Dako REAL peroxidase-blocking solution (Dako-
Cytomation, Glostrup, Denmark) for 5min to block endogenous
peroxidase. Immunostaining was performed by adding mouse
monoclonal c-myc (9E10) antibody (Santa Cruz, Santa Cruz, CA,
USA, diluted 1:400 in Dako REAL antibody diluent, Biohit,
Helsinki, Finland); or mouse monoclonal Bmi-1 (ab 14389)
(Abcam, Cambridge, UK, 1:400); or rabbit polyclonal Snail
(ab17731) (Abcam, 1:2000); or monoclonal mouse Ki-67 Antigen
(DakoCytomation, 1:100) for 1h, followed by a 30min incubation
with the Dako REAL EnVision/HRP detection system. Rabbit/
mouse (ENV) reagent slides were finally visualised using Dako
REAL DABþ chromogen for 10min. Between each step, slides
were washed with PBS–0.04% Tween20. Slides were counter-
stained with Meyer’s haematoxylin and mounted in mounting
medium (Aquamount, BDH, Poole, UK). In every immunohisto-
chemical staining batch, we used a specific positive control for
every antibody used. As a negative control, specimens diluted
without a primary antibody were used. As negative/positive
controls, we used reactive lymph node tissue, showing a negative
and a positive Bmi staining pattern (Raaphorst et al 2000; Dutton
et al 2007) (not shown). As a positive control for c-myc and Snail
immunohistochemistry, breast and ovarian carcinoma tissue
samples were used (not shown).
Evaluation of immunostainings
Immunostainings were evaluated by two independent pathologists
(JH and HS) without knowledge of clinical data. The percentage of
positive tumour cells was evaluated. No positivity was graded as 0,
up to 30% positive cells were graded as 1 (very low), 30–50% as 2
(low), 50–80% as 3 (moderate), and over 80% as 4 (high).
Evaluation was carried out according to Buduneli et al (2007).
Bmi-1 and Snail positivity was nuclear and c-myc scoring was
carried out as both nuclear and cytoplasmic. Each patient was
expected to have six spots, and for each patient we selected the
highest immunoscore for further analysis.
Statistical analysis
For categorical, non-ordered variables, cross tabulations were
analysed using the w
2-test, or when the w
2-test was not valid,
Fisher’s exact test was used. All P-values are two-sided and
exact. In survival analysis, an event was defined as evidence of
disease in any form, including local recurrence, neck metastasis,
distant metastasis, or death of the primary disease verified in
autopsy.
Follow-up time was calculated from the date of first treatment
(surgery) until event, and patients alive and disease free or
deceased from non-tumour-related causes were censored on the
last date of follow-up. Kaplan–Meier curves were plotted from
follow-up data and the log-rank test was used to compare outcome
between patient categories. The Cox multivariate regression
analysis was used to control for confounding factors. SPSS version
15.0 software (SPSS, Chicago, IL, USA) was used.
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Bmi-1, c-myc, and Snail protein expression
Bmi-1 protein expression was detected in 82%, nuclear c-myc
expression in 63%, cytoplasmic c-myc expression in 73%, and
Snail expression in 100% of all tumours. Bmi-1 expression,
when present, ranged from very low to high frequency of
immunoreactive cells. Nuclear c-myc expression was usually
observed at a low frequency, in less than 50% of tumour cells. In
only two cases was high frequency of nuclear c-myc expression
found (450%). Snail expression was observed in all samples, with
the majority of tumour cells being immunoreactive. However,
regarding Snail expression, two groups of patients could be
distinguished, one with less than 80% immunoreactive cells and
another in which virtually all tumour cells expressed Snail protein
(480%). The different levels of protein expression are sum-
marised in Table 1 and examples of different patterns of protein
expression are shown in Figures 1 and 2.
Bmi-1 protein expression is a prognostic marker
In a Kaplan–Meier survival analysis, a correlation between Bmi-1
protein expression and recurrence (log-rank test, P¼0.005) was
detected (Figure 3). The absence of Bmi-1 protein in the tumour
cells was associated with a higher risk of recurrence. During the
follow-up time of this study, only three patients died of OSCC. It is
noteworthy that all three deaths occurred in Bmi-1-negative cases.
The majority of patients remained disease free during follow-up.
Therefore, the primary end point for survival analyses was defined
as recurrence of disease. For statistical analysis, cases were
grouped into three categories: Bmi-1 negative, low, and a high
proportion of positive immunoreactive tumour cells. The mean
disease-free time for Bmi-1-negative cases was 53 months (95% CI
29–77 months), whereas patients with tumours with a high
frequency of Bmi-1-expressing cells had a mean disease-free time
of 112 months (95% CI 97–126 months).
To rule out confounding factors, a multivariate analysis was also
performed. In this, the depth of invasion, tumour size, margin of
surgical resection, and T classification were included, along with
the Bmi-1 protein expression score. In the Cox regression model,
Bmi-1 expression remained the only independent covariate
(P¼0.012). The other factors were not statistically significant.
The hazard ratio between absent Bmi-1 expression and high Bmi-1
expression was 5.2 (95% CI 1.5–18.3).
Although treatment of the neck does not directly reflect patient
or tumour characteristics, we also analysed the prognostic impact
of Bmi-1 expression with regard to the performed treatment. When
patients who received an elective neck treatment and those without
any elective neck treatment (observation only) were analysed
independently, Bmi-1 expression was prognostic only in the
group of patients in whom neck treatment was performed
(log-rank test, P¼0.004). However, the group of patients who
did not receive neck treatment is smaller (28 cases analysed) than
the group of patients who received elective neck treatment (42
cases); therefore, this lack of statistical significance is probably due
to the small sample size. This is also the case when analysing
disease-free survival times separately for recurrences in lymph
nodes. Only 16 cases presented lymph node recurrence, and
therefore a reliable statistical analysis is not possible.
Prognostic significance of c-myc, Snail, and ki-67 protein
expression
Survival analyses for the expression of c-myc, Snail, and Ki-67
were performed in an identical manner as that for Bmi-1, with
tumour recurrence as the primary end point. For Snail,
tumours were first grouped into two categories: high (480%)
and moderate (o80%) frequency of immunoreactive tumour cells.
Table 1 Expression of Bmi-1, C-myc, Snail, and Ki-67 in squamous cell
carcinoma of the tongue
Number of cases
Immunoexpression
scoring None Very low Low Moderate High Total
Bmi-1 13 25 17 10 5 70
C-myc(n) 27 35 6 2 0 70
C-myc(cp) 20 25 10 11 4 70
Snail 0 0 4 18 47 69
a
Ki-67 0 13 24 14 16 67
a
Abbreviations: C-myc(n)¼nuclear staining; C-myc(cp)¼cytoplasmic staining.
aFor
these markers, o70 representative samples were available. The frequency of
immunopositive tumour cells is shown. Bmi-1 and Snail expression is nuclear, C-myc
expression is presented separately for nuclear and cytoplasmic immunoreactivity. No
immunoreactive cells is scored as none, those with o30% positive cells as very low,
those with 30–50% as low, 51–80% moderate, and those with over 80%
immunoreactive tumour cells are scored as high.
Bmi-1
No positivity Very low positivity Low positivity Moderate High positivity
Snail
Figure 1 Scoring of immunohistochemical staining with Bmi-1 and Snail antibody: no cytoplasmic positivity, very low positivity is o30%, low positivity is
30–50%, moderate positivity is 51–80%, and high positivity is 480%.
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sNo statistically significant difference in outcome was observed
between patients with high and low Snail expression (log-rank test,
P¼ns) (not shown). Similarly, tumours were grouped according to
nuclear c-myc expression into negative (no expression) and
positive categories.
No statistically significant difference in outcome was found
between the c-myc negative and positive group (log-rank test,
P¼ns). There was no correlation between cytoplasmic c-myc
expression or Ki-67 staining and survival analyses, nor in outcome
(not shown).
Clinical and histopathological correlates
The protein expression levels of all the markers (Table 1) were
examined for correlations with clinical and histopathological
parameters. These included degree of histological differentiation,
tumour size, TNM classification, depth of invasion, and margin
of resection. Snail expression was significantly lower in well-
differentiated tumours, whereas in poorly differentiated tumours,
Snail expression was high (Fisher’s exact test, P¼0.007). Snail
protein expression was also found to correlate with depth of
invasion. In cases with the highest Snail score (480% positive
tumour cells), the depth of invasion was greater (w
2-test,
P¼0.037). Finally, the prognostic significance of the above-
mentioned clinicopathological features was also evaluated. In
brief, no other statistically significant correlations were found.
DISCUSSION
In this study, we examined the value of polycomb protein and
oncogene Bmi-1, as well as proto-oncogene c-myc, transcription
factor Snail, and proliferation marker Ki-67 expression, in a series
of 73 oral tongue carcinoma patients in relation to clinical
outcome.
We found a statistically significant correlation between lack of
Bmi-1 immunoexpression and poor prognosis of OSCC patients.
Interestingly, Bmi-1 overexpression has been earlier reported to be
constantly present in a small series of patients (N¼10) with oral
dysplastic and carcinoma tissue (Kang et al, 2007), but our
research data consisted of 73 patients. Although high Bmi-1
overexpression is connected to poor prognosis in nasopharyngeal
carcinoma (Song et al, 2006) and to non-small-cell lung cancer,
breast carcinoma, and hepatocellular carcinoma (Vrzalikova et al,
2008), in our data, Bmi-1-negative tumours showed a correlation
C-myc
nucl/cytopl
0/0 0/1 0/2 0/3
1/0 1/1 1/2 1/3
2/0 2/1 2/2 2/3






































Figure 3 Kaplan–Meier graph of Bmi-1 expression and disease-free
survival.
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swith poor prognosis. Several plausible explanations can be
found for this. First, the roles of polycomb proteins are
highly varied and depend on the composition of the polycomb
repressive complex that Bmi-1 is a part of. The target genes and
thus cellular functions such as migration, senescence, and
proliferation effect vary considerably (Spivakov and Fisher,
2007). Furthermore, Bmi-1 expression has been identified as a
prognostic factor only in certain types of cancer. For instance, in
gliomas, Bmi-1 expression is prognostic in oligodendroglial
tumours, in which its expression is abundant, whereas in the
much more aggressive high-grade astrocytomas and glioblastomas,
Bmi-1 expression is frequently very low and does not correlate
with prognosis (Ha ¨yry et al, 2008). The apparent difference
between the role of Bmi-1 in reported nasopharyngeal carcinoma
cases (Song et al, 2006) and our material of OSSC may also be
explained by the fact that nasopharyngeal carcinoma is a non-
keratinising type of carcinoma. Tongue carcinoma, on the other
hand, is a keratinising SCC and its behaviour may be different
from other cancer types.
C-myc expression in a microarray material has been lower in
oral carcinomas, compared with laryngeal or pharyngeal primary
carcinomas (Freier et al, 2003). This result may allude to the fact
that oral carcinomas are different diseases compared with their
counterparts in other anatomical sites. C-myc is presumed to take
part in early oral carcinogenesis, but according to our study,
nuclear c-myc immunoexpression did not show a significant
correlation with prognosis, although a tendency was observed.
C-myc mRNA downregulation has been shown to correlate with
poor prognosis and progression of the disease (Vora et al,2 0 0 7 ) .I n
this study, c-myc mRNA was not studied. In fact, Vora et al
observed an inverse correlation between cytoplasmic c-myc protein
expression and tumour stage. In our study, cytoplasmic c-myc
expression did not show any correlation with clinical parameters.
The discrepancy between these results may be caused by the small
sample size (n¼19) used in the study by Vora et al (2007).
In this material, Ki-67 immunostaining did not provide any
relevant prognostic information.
Snail has been shown to be active in OSSC and, concurrently, we
found a positive expression in all our samples. Snail expression
correlated with invasion depth in our material, suggesting a role in
the primary invasiveness of OSCC. Indeed, tumour thickness has
been found to correlate with metastasis, local recurrence, and
survival (Po Wing Yuen et al, 2002). However, this chain of events
did not directly reflect on the prognostic value of Snail expression,
which was not statistically significant. However, there was a
tendency for high Snail expression and poor prognosis. Although
Snail expression has previously been connected to lymph node
metastases and clinicopathological tumour stage in oesophageal
SCC (Usami et al, 2008), in our data, the high Snail expression was
correlated only to histopathological grading (well, moderate, or
poor differentiation). According to many studies, the histological
grading of OSCC does not correlate with clinical outcome (Keski-
Sa ¨ntti et al, 2007). This is in line with our results showing Snail
expression correlating with tumour grade but not with prognosis.
In OSCC, loss of the cadherin/catenin complex has been linked to
the degree of differentiation but not to metastatic disease. This is
in accordance with our findings, because Snail overexpression is
linked to lowered cadherin/catenin expression (Mahomed et al,
2007; Zidar et al, 2008).
In conclusion, loss of Bmi-1 immunoexpression seems to
correlate with clinical outcome of oral tongue SCC, in contrast to
Snail or c-myc immunoexpression. Snail expression correlates with
histological grading and depth of invasion. Our results suggest that
loss of Bmi-1 might serve as a clinically relevant marker for poor
prognosis in OSCC.
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